Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy-Reference-Cited by-同舟云学术

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy

Published:2016 Issue:6 Volume:1 Page:esmoopen-2016-000117
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Milani Andrea,Kristeleit Rebecca,McCormack Mary,Raja Fharat,Luvero Daniela,Widschwendter Martin,MacDonald Nicola,Mould Tim,Olatain Adeola,Hackshaw Allan,Ledermann Jonathan A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Overview of Ovarian Cancer in England;Trent Cancer Registry,2012

2. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004);du Bois;Ann Oncol,2005

3. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer;du Bois;J Natl Cancer Inst,2003

4. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group);McGuire;Semin Oncol,1996

5. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study;Muggia;J Clin Oncol,2000

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ovarian Cancer: Primary Advanced and Recurrent Disease;Practical Medical Oncology Textbook;2021

2. Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer;International Journal of Environmental Research and Public Health;2020-03-26

3. Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer;International Journal of Environmental Research and Public Health;2019-11-29

4. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer;Nature Communications;2019-03-20

5. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience;Journal of Ovarian Research;2018-05-30